Rankings / Hormones & Endocrine
Clascoterone (Winlevi) for hair loss
Hormones & Endocrine · Topical androgen receptor antagonist
Tier B+
Bottom line
Read Off Label grades Clascoterone (Winlevi) for hair loss as B+ (7.1/10) based on moderate evidence, med benefit magnitude, and a low-risk safety profile.
Cassiopea/Sun Pharma.
Studied, labeled, or reported-use context: Topical cream/solution to scalp — Rx (approved 2020 for acne as Winlevi); AGA off-label / Phase 2-3; not individualized guidance.
What the evidence says
Cassiopea/Sun Pharma. FDA-approved 2020 for acne (Winlevi); hair-growth Phase 2 data support an androgenetic-alopecia program, Phase 3 pending. A non-systemic topical anti-androgen, complementary/competitive with pyrilutamide and topical finasteride. Industry-sponsored.
Mechanism
Topical androgen-receptor antagonist (approved for acne) in development for androgenetic alopecia, with local anti-androgen action at the follicle without systemic anti-androgen exposure.
Studied, labeled, or reported dose & route
Topical cream/solution to scalp
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Clascoterone (Winlevi) for hair loss's effects?
- Read Off Label rates the evidence for Clascoterone (Winlevi) for hair loss as Moderate and the benefit magnitude as med, producing an overall grade of B+ (7.1/10). Cassiopea/Sun Pharma.
- What safety findings are reported for Clascoterone (Winlevi) for hair loss?
- Clascoterone (Winlevi) for hair loss has a low risk profile in the database. Low (topical; local skin effects) Legal status: Rx (approved 2020 for acne as Winlevi); AGA off-label / Phase 2-3.
- What doses or routes are reported for Clascoterone (Winlevi) for hair loss?
- Topical cream/solution to scalp This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Clascoterone (Winlevi) for hair loss work?
- Topical androgen-receptor antagonist (approved for acne) in development for androgenetic alopecia, with local anti-androgen action at the follicle without systemic anti-androgen exposure.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.